LVGN-6051 is under clinical development by Lyvgen Biopharma and currently in Phase I for Soft Tissue Sarcoma. According to GlobalData, Phase I drugs for Soft Tissue Sarcoma have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how LVGN-6051’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

LVGN-6051 overview

LVGN-6051 is under development for the treatment of advanced or metastatic malignancy including lung cancer, melanoma, B-cell non-Hodgkin’s lymphoma, non-small cell lung cancer, gastrointestinal tract cancer and lymphoma. It is a humanized monoclonal antibody that acts by targeting CD137 and FCGR2B. It is administered through intravenous infusion. The drug candidate is developed based on cross-link antibody (xLinkAb) platform.

Lyvgen Biopharma overview

Lyvgen Biopharma, is a cancer immunotherapy service provider. The company is headquartered in China.

For a complete picture of LVGN-6051’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.